George Demetri Insider Profile
4 Followers
George Demetri, former Director at Blueprint Medicines, holds 8.41K shares in Blueprint Medicines (Ticker: BPMC), holds ― shares in Merrimack Pharmaceuticals (Ticker: MACK), holds ― shares in Translate Bio (Ticker: ~TBIO).
George Demetri's Trading History
| BPMCBlueprint Medicines | Jun 30, 2022 | ― | Uninformative Buy | ― | $1.09M | |
| ~TBIOTranslate Bio | ― | ― | ― | ― | ||
| MACKMerrimack Pharmaceuticals | ― | ― | ― | ― |
You May Also Like
George Demetri insider profile FAQ
What is the percentage of profitable transactions made by George Demetri?
The percentage of profitable transactions made by George Demetri is 50%.
What is the average return per transaction made by George Demetri?
The average return per transaction made by George Demetri is 12.50%.
What stocks does George Demetri hold?
George Demetri holds: BPMC, MACK, ~TBIO stocks.
What was George Demetri's most profitable transaction?
George Demetri’s most profitable transaction was an Informative Buy of BPMC stock on June 30, 2022. The return on the trade was 25.10%.
What is George Demetri's role in Blueprint Medicines?
George Demetri's role in Blueprint Medicines is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
